Pacira BioSciences
PCRX
211 hedge funds and large institutions have $1.72B invested in Pacira BioSciences in 2019 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 71 increasing their positions, 61 reducing their positions, and 46 closing their positions.
61% more call options, than puts
Call options by funds: $6.54M | Put options by funds: $4.05M
16% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 61
4.78% more ownership
Funds ownership: 103.6% → 108.38% (+4.8%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
9% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 46
3% less funds holding
Funds holding: 218 → 211 (-7)
8% less capital invested
Capital invested by funds: $1.86B → $1.72B (-$141M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$137M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$47.9M |
| 3 |
PC
Paulson & Co
New York
|
+$30.2M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$21M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$122M |
| 2 |
Millennium Management
New York
|
-$33.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$33.3M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$31.9M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$20.3M |
PCRX Hedge Fund Activity: Q3 2019 in Review
211 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2019, worth a combined $1.72B — down 7.6% from $1.86B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of PCRX and 42 opened new positions — a net loss of 4 holders — while 61 trimmed existing stakes and 71 added.
The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $122M sold.
- 211 institutional investors held Pacira BioSciences (PCRX) as of Q3 2019, down from 218 in Q2 2019.
- Funds reported $1.72B of Pacira BioSciences stock for Q3 2019, down 7.6% quarter-over-quarter.
- 42 funds opened new Pacira BioSciences positions in Q3 2019 and 46 closed out, a net change of -4 holders.
- The largest Pacira BioSciences buyer in Q3 2019 was BlackRock, an estimated $137M added.
- The largest Pacira BioSciences seller in Q3 2019 was Consonance Capital Management, an estimated $122M sold.
Based on aggregated 13F filings for Q3 2019.